GO
Loading...

Enter multiple symbols separated by commas

Stocks Actavis Inc

More

  • July 27- U.S. stock index futures fell sharply on Monday on concerns about China's slowing growth in the wake of the biggest drop in Shanghai shares in eight years. *Chinese ADRs were set for a rough start with Alibaba, Baozun and Sohu.com off between 2 percent and 5 percent. *Second-quarter S&P 500 earnings have been mixed, with 74 percent of companies beating...

  • TEL AVIV, July 27- Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a deal that will turn Teva into one of the top 10 pharmaceutical companies. Allergan's generic business is generally seen as a better fit than Teva's previous target Mylan because it will improve Teva's distribution channels and...

  • TEL AVIV, July 26- After months of sparring in a hostile takeover bid for rival Mylan NV, Teva Pharmaceutical's move to buy Allergan Plc's generic drug business instead could be a smoother ride that will bring bigger returns, faster. Israel- based Teva, the world's largest generic drugmaker, is in advanced talks to buy Allergan's generic drugs unit for between $40-...

  • July 25- Teva Pharmaceutical Industries Ltd is in advanced talks to buy Allergan Plc's generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV, according to a person familiar with the matter. Jerusalem- based Teva, which has offered to buy Mylan for $40 billion, is now close to an agreement to acquire Dublin- based Allergan's...

  • July 25- Israeli drug maker Teva Pharmaceutical Industries Ltd is in talks to combine with Allergan Plc's big generic-drug business, the Wall Street Journal reported on Saturday, citing people familiar with the matter. A deal for the Allergan business, valued at about $45 billion, could be announced as early as Monday, one of the people said, according to the...

  • July 24- Allergan Plc is considering a breakup of the company into two businesses, a person familiar with the matter told Reuters on Friday. Allergan is considering keeping its branded drugs business but spinning off or selling parts or all of its generics business, according to the person who asked not to be identified because the deliberations are...

  • July 24- Botox-maker Allergan Plc is exploring a breakup of the company into two businesses, eight months after forming a multi-billion dollar pharmaceutical company through a merger with Actavis Plc, Bloomberg reported on Friday, citing sources. Allergan's shares were up 3.8 percent in extended trading after closing at $308.21 on Friday.

  • July 13- Anacor Pharmaceuticals Inc's experimental skin ointment succeeded in late-stage studies, taking the drugmaker a step closer to having a potential blockbuster in its portfolio and raising expectations that it could be taken over. "Personally, I'd love to see Anacor independent a little bit longer, but I don't think its going to happen," said Paul Yook,...

  • US STOCKS-Wall St dips as investors edgy ahead of Fed meet Wednesday, 17 Jun 2015 | 12:57 PM ET

    *Fed statement at 2 p.m. ET; Yellen conference at 2:30 p.m.. *Apple weighs on Nasdaq, S&P; UnitedHealth biggest drag on Dow. The Fed statement will be followed by Chair Janet Yellen's news conference half an hour later.

  • *Fed statement at 2 p.m. ET; Yellen conference at 2:30 p.m.. The Fed statement is due at 2:00 p.m. ET, followed by Chair Janet Yellen's news conference half an hour later, with analysts expecting her to focus on signs the economy is recovering after a bumpy start to the year. "The Fed will send out another message which lays down the groundwork for a rate rise in August...

  • June 17- Wall Street was set to open little changed on Wednesday as investors were reluctant to add to positions ahead of a Federal Reserve statement that could provide hints on the timing of a rate hike. The Fed statement is due at 2:00 p.m. ET, followed by Chair Janet Yellen's news conference half an hour later, with analysts expecting her to focus on signs the...

  • June 17- Botox-maker Allergan Inc said it would buy Kythera Biopharmaceuticals Inc in a cash-and-stock deal valued at about $2.1 billion, to expand its line of cosmetic treatments. The offer price of $75 per Kythera share represents a premium of 23.5 percent to the stock's Tuesday close. Buying Kythera will give Allergan access to Kybella, the first and only...

  • June 5- Orexigen Therapeutics Inc and partner Takeda Pharmaceutical Co Ltd said they had filed a lawsuit against Actavis Plc to block a generic version of diet-pill Contrave. The lawsuit, filed at a Delaware district court, alleges that Actavis has infringed patents on Orexigen and Takeda's weight-loss treatment. Actavis and Teva Pharmaceutical Industries...

  • NEW YORK, May 22- Actavis Plc cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier extended-release version, a federal appeals court in New York ruled on Friday. The decision at the 2nd U.S. Circuit Court of Appeals is a win for New York State Attorney General Eric Schneiderman, who sued to block the switch, arguing that Actavis was...

  • NEW YORK, May 22- Actavis Plc cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier extended-release version, a federal appeals court ruled on Friday. A three-judge panel at the 2nd U.S. Circuit Court of Appeals in New York upheld an order by U.S. District Robert Sweet in December requiring Actavis to keep the older drug, Namenda IR, on the...

  • May 14- Drug maker Actavis Plc said its Warner Chilcott unit held talks with U.S. government officials to discuss a potential resolution of an investigation into the unit's sales activities, according to a regulatory filing. Warner Chilcott said the company and several of its employees in the sales organization received subpoenas in 2012 from the United...

  • *Actavis initial forecast historically conservative- analysts. Sales of Allergan products for 15 days and the drugs acquired with the Forest Laboratories deal helped Actavis beat revenue estimate in the quarter ended March 31. Actavis, whose shares were up 3 percent, outbid Canadian drugmaker Valeant Pharmaceuticals International Inc and activist...

  • US STOCKS-Wall St mixed at open; energy shares fall Monday, 11 May 2015 | 10:27 AM ET

    *Rosetta soars as Noble Energy offers to buy company for $2 bln. *Zulily rises after Alibaba increases stake. Exxon Mobil shares fell 1.1 percent to $87.28.

  • *Rosetta soars as Noble Energy offers to buy company for $2 bln. *Zulily rises after Alibaba increases stake. "There will be some carry-over from the positive jobs report but not at the same magnitude," said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.

  • May 11- Drugmaker Actavis Plc, which completed its $66 billion acquisition of Botox maker Allergan in March, reported a better-than-expected quarterly profit, helped by higher sales of its branded drugs in North America. Actavis forecast 2015 revenue of $20.5 billion to $21 billion on Monday. Actavis said first-quarter results included business from...